Evidence map›Paper›PMID 26265184›Full record

ReviewLeukemia2016

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.

S Lonial, B Durie, A Palumbo, J San-Miguel

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Eastern Cooperative Oncology Group,Frontiers in microbiology · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

S LonialHematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
B DurieCedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.
A PalumboDepartment of Hematology, University of Torino, Torino, Italy.
J San-MiguelClínica Universidad de Navarra, Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment landscape for patients with multiple myeloma (MM) is constantly evolving. Over the past decade, the introduction of novel agents such as proteasome inhibitors and immunomodulatory drugs has led to notable changes in therapeutic strategy, and improvements in survival, yet MM remains incurable in the vast majority of cases. More recently, a targeted approach to MM treatment has emerged, using monoclonal antibodies (mAbs) to target antigens expressed on the surface of MM cells. MAbs tested to date kill MM cells via the host's immune system and/or by promoting apoptosis, and appear to have generally improved tolerability compared with currently available treatments. Due to their distinct mode of action, mAbs are promising both for patients who have exhausted current regimens, and as part of first-line treatments in newly diagnosed patients. This review examines the recent developments in mAb-based therapy for MM, primarily focused on those agents in ongoing clinical testing.

Indexed as

Antibodies, MonoclonalAntigens, CDApoptosisB-Cell Activating FactorDisease-Free SurvivalGene ExpressionHumansImmunologic FactorsImmunotherapyInterleukin-6Interleukin-6 InhibitorsMultiple MyelomaPlasma CellsProteasome InhibitorsReceptors, CXCR4Receptors, ImmunologicAntibodies, MonoclonalAntigens, CDB-Cell Activating FactorCXCR4 protein, humanIL6 protein, humanImmunologic FactorsInterleukin-6Interleukin-6 InhibitorsProteasome InhibitorsReceptors, CXCR4Receptors, ImmunologicSignaling Lymphocytic Activation Molecule FamilySLAMF7 protein, humanTNFSF13B protein, human

Identifiers

PMID26265184
PMCPMC4777772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.